Cessation of Long-term Opioid Therapy in Chronic Pain Patients

This is an interventional treatment trial for Chronic Pain focused on measuring Chronic non cancer pain, Long term opioid therapy, Side effects, risks, function, negative benefit/risk ratio Read More

Inclusion Criteria:

• Male or Female, age above 18.
• Chronic non-cancer pain (pain for 6 or more months, current pain not attributed to a cancerous disease).
• Referrals to the Massachusetts General Hospital (MGH) Center for Pain Medicine for opioid taper.
• Chronic (more than 3 months) prescription of morphine, oxycodone, hydrocodone, hydromorphone, codeine or any formulation of these medications.
• Morphine dose equivalent of 60 mg or above.
• Opioid treatment has to be stable (plus or minus20%) over the last 3 months.
• Meeting Substance Abuse and Mental Health Services Administration (SAMHSA) criteria for exit from chronic opioid therapy
• Willingness to taper and participate in treatment as randomized (including cognitive workshop sessions), able to meet the protocol follow-up schedule and activities
• Agreement to undergo random urine toxicology assays, which will be recommended to prescribing physician during study.
• Agreement to sign an opioid contract, as recommended to prescribing physician.
• Informed consent to study (IRB approved informed Consent form).
• English Language Literacy.

Exclusion Criteria:

• Methadone, suboxone or fentanyl patch: the tapering with these opioids would not be comparable to the other patients. As enrolment will be open during about 12 months, if a patient was motivated to participate in the study, they could be referred to the pain clinic for advice on a switch to a medication that could allow inclusion. They would, 3 months after this switch, become eligible for the study.
• Pregnancy.
• History of epilepsy and drug-induced seizures.
• Proof of current diversion of drugs or recent substance related legal problems (e.g. buying/selling on the streets).
• Concurrent use of illicit drugs and narcotics (urine toxicology), active diagnosis of substance abuse or dependence disorder within last 3 months.
• Absence of the prescribed drug in the urine toxicology
• Refusal of taper or dose reduction trial.
• Preference for suboxone or related treatments.
• Severe psychiatric condition and/or cognitive deficits limiting patient's ability to participate
• Involved in concurrent opioid management for an acute pain condition.
• Current suicidal ideation.
• Severe and unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological or hematological disease.
• General conditions that would impede participation in a group intervention, as assessed by evaluating physician (e.g. cognitive impairment, tendencies towards physical aggression).